Can metformin or colchicine ease long COVID? major trial launches

NCT ID NCT07280572

First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 27 times

Summary

This Phase 3 trial is testing whether two widely available drugs—metformin and colchicine—can improve physical health and reduce symptoms like fatigue in people with long COVID. About 1,250 adults in the Netherlands will take one of the drugs or receive usual care for 12 weeks, with all participation done remotely via video calls and home delivery. The goal is to find safe, practical treatments for the millions struggling with persistent post-COVID symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-COVID CONDITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Netherlands

    Utrecht, Netherlands

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metformin and colchicine

What this could lead to

If successful, this could point toward simple, repurposed drugs to improve quality of life for people with long COVID.

What could go wrong

This is an early-stage platform trial, and the drugs may not prove effective for long COVID. Side effects from metformin or colchicine are possible.

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.